Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants [Phase 3]

View source ↗

Summary

Phase 3 pediatric trial evaluating Dimethyl Fumarate and Peginterferon Beta-1a for relapsing-remitting multiple sclerosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Dimethyl fumarate (Dimethyl fumarate)
• Peginterferon beta-1a (peginterferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: TERMINATED | Results posted: 2023-05-16